ELAVL1 and neoplasm: Critically, we identified HuR as a dual-function biomarker: it exhibits >85% diagnostic accuracy through integrated TMB/PD-L1 evaluation and demonstrates prognostic value via association with immunosuppressive (“cold”) tumor microenvironments and immune checkpoint inhibitor (ICI) resistance.